文献速递消化道肿瘤放疗

诱导化疗后卡培他滨联合同步中度大分割放疗治疗晚期胰腺腺癌

Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-04-12

本研究评估诱导化疗后无远处进展的晚期胰腺癌患者接受44.25 Gy/15次大分割放疗联合同步卡培他滨1250 mg/m2/天的可行性、毒性和疗效。254例患者(220例III期,34例IV期)接受治疗,中位随访19个月,III期患者中位总生存19.5个月,1年和2年生存率分别为85.2%和36%。作者结论认为该方案可行、毒性可接受,疗效与标准剂量分割相当。

要点

  • 诱导化疗后无远处进展的晚期胰腺癌患者可考虑44.25 Gy/15次大分割放疗联合同步卡培他滨。
  • 同步放化疗期间G3胃肠道毒性发生率为3.2%,G3-G4血液学毒性为5.4%。
  • III期患者中位OS为19.5个月,1年和2年生存率分别为85.2%和36%。

核心结论

  • 作者结论认为,诱导化疗后大分割放疗方案可行,毒性率可接受,疗效与标准剂量分割方案相当。

研究设计与样本

  • 本研究为单臂可行性评估研究,纳入诱导化疗后无远处进展的晚期胰腺癌患者。
  • 放疗方案为肿瘤及受累淋巴结44.25 Gy/15次,同步卡培他滨1250 mg/m2/天。
  • 所有患者评估可行性和毒性,仅III期患者评估OS、PFS、DPFS和LPFS。
  • 共254例患者接受治疗,其中III期220例,IV期34例。

主要发现

  • 中位随访19个月,诱导化疗中位持续时间6个月。
  • 4例(1.6%)未完成放疗(1例早期进展,3例毒性),放疗中位持续时间20天,209例(82%)接受≥75%卡培他滨剂量。
  • 同步放化疗期间G3胃肠道毒性发生率为3.2%,G3-G4血液学毒性发生率为5.4%。
  • 后续发生G3、G4、G5胃或十二指肠病变者分别为10例(4%)、2例(0.8%)和1例(0.4%)。
  • III期患者中位PFS为11.9个月(95%CI:11.4-13),中位LPFS为16个月(95%CI:14.2-17.3),中位DPFS为14.0个月(95%CI:12.6-146.5,原文如此)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To assess feasibility, toxicity and outcome of moderately hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic cancer. MATERIALS AND METHODS: Patients with advanced pancreatic cancer without distant progression after induction chemotherapy (CHT) were considered. Radiochemotherapy (RCT) consisted of 44.25 Gy in 15 fractions to the tumor and involved lymph-nodes concomitant to capecitabine 1250 mg/m2/day. Feasibility and toxicity were evaluated in all pts. Overall survival (OS), progression free survival (PFS), distant PFS (DPFS) and local PFS (LPFS) were assessed only in stage III patients. RESULTS: 254 patients, 220 stage III, 34 stage IV, were treated. Median follow up was 19 months. Induction CHT consisted of Gemcitabine (35 patients), or drug combination (219 patients); median duration was 6 months.Four patients (1.6 %) did not complete RT (1 early progression, 3 toxicity), median duration of RT was 20 days, 209 patients (82 %) received ≥ 75 % of capecitabine dose.During RCT G3 gastrointestinal toxicity occurred in 3.2% of patients, G3-G4 hematologic toxicity in 5.4% of patients. Subsequently, G3, G4, G5 gastric or duodenal lesions occurred in 10 (4%), 2 (0.8%) and 1 patients (0.4%), respectively.Median PFS, LPFS, and DPFS were 11.9 months (95 % CI:11.4-13), 16 months (95 % CI:14.2-17.3) and 14.0 months (95 % CI:12.6-146.5), respectively.Median OS was 19.5 months (95 % CL:18.1-21.3). One- and two-year survival were 85.2 % and 36 %, respectively. CONCLUSIONS: The present schedule of hypofractionated RT after induction CHT is feasible with acceptable toxicity rate and provides an outcome comparable with that achievable with standard doses and fractionation.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Passoni P, Reni M, Broggi S, et al. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. Clin Transl Radiat Oncol. 2024. PMID: 38779525. doi:10.1016/j.ctro.2024.100778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。